COPD Exacerbation Clinical Trial
— SIRCAPOfficial title:
A Prospective Study of Salvational Intervention With ICS/LABA for Reducing Chronic Obstructive Pulmonary Disease Exacerbation Under Severe Air Pollution (SIRCAP) in Beijing
Verified date | March 2022 |
Source | Peking University First Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multi-center, prospective, randomized and standard treatment parallel control clinical trial.A total of 764 stable COPD patients according to GOLD will be recruited and equally divided into two parallel groups, salvational intervention group (SI group) and control group (CT group).On the foundation of basic medicine, inhaled ICS/LABA will be used as an intervention drug for patients in SI group on severe air pollution days. It is aimed to evaluate whether this novel treatment strategy will decrease the frequency of AECOPD per year.
Status | Completed |
Enrollment | 402 |
Est. completion date | March 16, 2022 |
Est. primary completion date | March 16, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. aged at 40-80 years old; 2. spirometry confirmed diagnose of COPD with at least once exacerbation before, and stable for at least three months; 3. quit smoking for more than six months; 4. be able to engage in daily activities; 5. have willing to participate in this study, follow the research program and have the ability to sign the informed consent; 6. Beijing residents; 7. can be contacted; Exclusion Criteria: 1. history of asthma, lung cancer, active pulmonary tuberculosis, bronchiectasis, diffuse lung disease (interstitial pneumonia, pulmonary sarcoidosis, occupational lung disease, sarcoidosis et al) and pleural disease; 2. history of lobectomy and / or lung transplantation; 3. predicted life expectancy less than 3 years; 4. history of severe psychiatric illnesses, mental disorders, neurological disorders, malignant tumors, chronic liver disease, heart failure, autoimmune diseases, chronic kidney disease; 5. Never engage in outdoor activities; 6. plan to move out of Beijing in 3 years 7. Plan to carry out an indoor redecoration during the study; 8. Alcoholism, drug abuse or abuse of toxic solvents; 9. Allergic to the study drug or its ingredients, or have a clear contraindication of it; 10. Participation in another clinical trial; 11. Cannot finish long term follow-up or poor compliance; 12. Do not provide consent. |
Country | Name | City | State |
---|---|---|---|
China | Aerospace 731 Hospital | Beijing | Beijing |
China | Beijing Changping Hospital | Beijing | Beijing |
China | Beijing Jingmei Group General Hospital | Beijing | Beijing |
China | Beijing Jishuitan Hospital | Beijing | Beijing |
China | Beijing Luhe Hospital | Beijing | Beijing |
China | Beijing Miyun Hospital | Beijing | Beijing |
China | Civil Aviation General Hospital | Beijing | Beijing |
China | Peking University First Hospital | Beijing | Beijing |
China | Peking University Shougang Hospital | Beijing | Beijing |
China | People's Hospital of Beijing Daxing District | Beijing | Beijing |
China | The Hospital of Shunyi District Beijing | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University First Hospital | Aerospace 731 Hospital, Beijing Changping Hospital, Beijing Jingmei Group General Hospital, Beijing Jishuitan Hospital, Beijing Luhe Hospital, Beijing Miyun Hospital, Civil Aviation General Hospital, Peking University Shougang Hospital, People's Hospital of Beijing Daxing District, The Hospital of Shunyi District Beijing |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the frequency of exacerbation of COPD per year | 3 year | ||
Secondary | the number of unplanned outpatient visits caused by exacerbation of COPD per year | 3 years | ||
Secondary | the number of unplanned emergency medical visits caused by exacerbation of COPD per year | 3 years | ||
Secondary | the number of unplanned hospitalization caused by exacerbation of COPD per year | 3 years | ||
Secondary | the cost of unplanned medical expense caused by exacerbation of COPD per year | 3 years | ||
Secondary | the number of unplanned mortality caused by exacerbation of COPD per year | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06000696 -
Healthy at Home Pilot
|
||
Recruiting |
NCT03250000 -
Changes in Microcirculation and Functional Status During Exacerbation of COPD
|
N/A | |
Recruiting |
NCT04142827 -
The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX)
|
N/A | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT01892566 -
Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV
|
N/A | |
Completed |
NCT04119856 -
Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD
|
N/A | |
Recruiting |
NCT06118632 -
Physiological and Environmental Data in a Remote Setting to Predict Exacerbation Events in Patients With Chronic Obstructive Pulmonary Disease
|
||
Recruiting |
NCT04860375 -
Multidisciplinary Management of Severe COPD
|
N/A | |
Completed |
NCT04170361 -
The Effect of Incentive Spirometry Added to Routine Physiotherapy Program on Hemodynamic Responses and Hospital Stay in Patients With COPD Exacerbation
|
N/A | |
Not yet recruiting |
NCT03696563 -
FreeO2 PreHospital - Automated Oxygen Titration vs Manual Titration According to the BLS-PCS
|
N/A | |
Not yet recruiting |
NCT03296215 -
Pattern of Admitted Cases in Respiratory Intensive Care Unit at Assiut University Hospitals
|
N/A | |
Completed |
NCT03003702 -
Domiciliary Monitoring to Predict Exacerbations of COPD
|
N/A | |
Completed |
NCT02912689 -
NIV - NAVA vs NIV - PS for COPD Exacerbation
|
N/A | |
Recruiting |
NCT02264483 -
Low-dose CT for Diagnosis of Pneumonia in COPD Exacerbations and Comparison of the Inflammatory Profile.
|
N/A | |
Completed |
NCT01443845 -
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
|
Phase 4 | |
Recruiting |
NCT02065921 -
Swiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort
|
||
Completed |
NCT04880486 -
Weight Training With VR in Out-Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
|
N/A | |
Recruiting |
NCT03286127 -
Palliative Outcome Evaluation Muenster I
|
||
Recruiting |
NCT04638920 -
Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy
|
||
Not yet recruiting |
NCT05897125 -
Telehealth Education Leveraging Electronic Transitions Of Care for COPD Patients
|
N/A |